Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
Apellis Pharmaceuticals (APLS) Stock Price & Analysis
416 Followers
APLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$37.66 - $94.45
Previous Close$92.13
Volume900.96K
Average Volume (3M)1.65M
Market Cap
$10.73B
Enterprise Value$10.07B
Total Cash (Recent Filing)$766.38M
Total Debt (Recent Filing)$111.87M
Price to Earnings (P/E)-14.7
Beta0.79
Next Earnings
Aug 07, 2023EPS Estimate
-$1.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.28
Shares Outstanding116,457,008
10 Day Avg. Volume1,041,931
30 Day Avg. Volume1,650,634
Standard Deviation0.18
R-Squared0.15
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)26.42
Price to Sales (P/S)177.96
Price to Cash Flow (P/CF)-15.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue95.15
Enterprise Value/Gross Profit144.37
Enterprise Value/Ebitda-15.31
Forecast
1Y Price Target
$104.54Price Target Upside15.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Apellis Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $37.66 and its highest was $94.45 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Aug 07, 2023 which is in 59 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on May 04, 2023. The company reported -$1.56 earnings per share for the quarter, missing the consensus estimate of -$1.478 by -$0.082.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -$1.37.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 116,457,010 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$1.56 in its last earnings report, missing expectations of -$1.478. Following the earnings report the stock price went up 10.442%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds Apellis Pharmaceuticals Inc’s shares valued at 37M.
---
Apellis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$104.54 (15.94% Upside)
$104.54 (15.94% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 397.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.14%
12-Months-Change
Fundamentals
Return on Equity
-158.06%
Trailing 12-Months
Asset Growth
-14.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
Top 5 ETFs holding APLS
Vanguard Health Care ETF
$25.79M
iShares Core S&P Total U.S. Stock Market ETF
$8.67M
iShares NASDAQ US Biotechnology UCITS ETF
$4.77M
Schwab U.S. Broad Market ETF
$4.36M
Fidelity MSCI Health Care Index ETF
$3.73M
Up to five ETFs with an Outperform Smart Score that hold APLS. The ETFs are listed according to market value of APLS within the ETF
---
Rocket Pharmaceuticals
―
Crispr Therapeutics AG
―
Ultragenyx Pharmaceutical
―
Bluebird Bio
―
---